PHARMACOGENOMICS STUDIES OF HUMAN HYPERTENSION

高血压（HTN）是一个多因素的特征，而控制老年人血压（BP）的药物方法尚未有效。因此，大多数患有HTN的美国人无法控制他们的血压。不同降压药物之间的相互比较存在研究空白。作为GenHAT（高血压相关治疗遗传学）研究的一部分，该研究将关注交感神经系统在HTN中作用的遗传易感性。本研究的主要目的是确定多个HTN易感基因在α -受体阻滞剂对BP反应的个体差异中的作用。这项研究将是一个实验性的实验室设计。可用于分析的样本量为9,081例随机分配到a受体阻滞剂doxazosin的患者。将探讨治疗-基因型相互作用。假设对doxazosin的反应会因选定的高血压变体而异。遗传学与BP药物治疗关系的研究可以指导未来针对患者HTN的病理进行干预，从而更有效地控制BP。

Hypertension (HTN) is a multifactoral trait, and pharmacological methods to control blood pressure (BP) in older adults have not been effective. As a result, the majority of Americans with HTN do not have their BP under control. A research gap exists in comparing the different antihypertensive pharmacological treatments with each other. The proposed study will focus on the genetic susceptibility of the sympathetic nervous system's role in HTN as part of the GenHAT (Genetics of Hypertension Associated Treatment) study. The primary specific aim for this study is to determine the role of multiple HTN susceptibility genes in interindividual variation in BP response to alpha-blockers. The study will be an experimental laboratory design. The sample size available for analysis is 9,081 patients that were randomly assigned to the a blocker doxazosin. Treatment-genotype interactions will be explored. It is hypothesized that the response to doxazosin will differ with selected hypertensive variants. A study on the relation of genetics and BP pharmacological treatment may direct future intervention that is specific for the pathology of the patient's HTN and, therefore, more effective at controlling BP.